课题基金 / 基金详情

SAFETY, TOLERANCE, PK ANTIVIRAL ACTIVITY OF FTC IN PATIENTS WITH HIV

SAFETY, TOLERANCE, PK ANTIVIRAL ACTIVITY OF FTC IN PATIENTS WITH HIV
FTC 在 HIV 患者中的安全性、耐受性和 PK 抗病毒活性
批准号：
6219488
负责人：
JAMES S KAHN
金额：
$0.06万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6219488
关键词：
AIDS therapy HIV infections antiAIDS agent clinical research clinical trial phase I drug resistance drug screening /evaluation human subject human therapy evaluation lamivudine nucleoside analog pharmacokinetics

项目摘要

项目成果

JAMES S KAHN的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The aim of a phase I monotherapy study in HIV-infected volunteers is to define and select a dose and schedule according to pharmacokinetics/ dynamics and tolerability. FTC is a nucleoside analogue that structurally resembles 3TC, but has 10-fold greater (in vitro) potency. In patients receiving 3TC alone, a fully resistant viral population develops within 12 weeks. Patients for this study must be 3TC naive.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Seek, Test, Treat and Retain strategies leveraging mobile health technologies
Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101
Adherence Improvement and Measurement- AIM- System. Challenge Topic 10-MH-101
Randomized controlled trial embedded in an electronic health record
海外基金